Although the specific mechanism of cell death induction of pancreatic cells remains to be analysed, from these biological studies, we can conclude that treatment with the peptidomimetic P1.3 kills pancreatic tumour cells expressing oncogenic KRAS, with a negligible effect in normal cells. Here, KRAS is linked to pancreatic neoplasm.